Exclusive

Genesis CEO Praises Court Decision, Blasts HRSA, NACHC, State Primary Care Association

Tony Megna, CEO and general counsel of Genesis Healthcare, shared his first public comments with 340B Report on a key 340B court decision.
In his first public comments since a key federal court decision on the 340B patient definition, the leader of a [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Exclusive

Lilly to Conduct HRSA-Approved Audit That Includes First-Time Look for Medicaid MCO Duplicate Discounts

Lilly
Eli Lilly is conducting government approved 340B provider audits that for the first time look for certain Medicaid health plan duplicate discounts.
Federal regulators have approved a first-time 340B provider audit by a drug manufacturer to examine processes to prevent duplicate discounts [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Exclusive

Federal 340B Leader Moves On After 21 Months

Lt. Cmdr. Emeka Egwim headshot
U.S. Public Health Service Lieutenant Commander Emeka Egwim left his position as director of OPA at HRSA 21 months after he started.
U.S. Public Health Service Lieutenant Commander Emeka Egwim left his position as director of the federal office overseeing the 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Exclusive

Health Centers Fear Losing 340B Pricing From Sanofi at Multiple Contract Pharmacies

Sanofi outdoor building sign
Changes to Sanofi's 340B drug pricing conditions may eliminate 340B discounts for health centers using multiple contract pharmacies within a chain.
Recent apparent changes to 340B drug pricing conditions by drug manufacturer Sanofi may eliminate 340B discounts for health centers using [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Exclusive

Large Drug Maker, Big Health System, and Influential Health Center Jointly Lobbying for Senate Bipartisan 340B Initiative

340B Working Table 340B lobbying disclosure form
Under the name 340B Working Table, Genentech, Sanford Health, and Carolina Health Centers are jointly lobbying for a bipartisan U.S. Senate 340B reform initiative.

Biopharmaceutical manufacturer Genentech, South Dakota-based health system Sanford Health, and South Carolina federally qualified health center Carolina Health Centers are jointly lobbying members of Congress to back six U.S. senators’ bipartisan approach to federal 340B program reform, the three organizations

Read More »

Exclusive

HRSA Says COVID Flexibility About Dispensing 340B Drugs in Unregistered Hospital Offsite Locations Will End Thursday

COVID-19 flexibility
HRSA has reversed course and will end a 340B COVID-19 flexibility that it previously said was permanent that lets hospitals under certain conditions start using 340B drugs at offsite outpatient locations sooner than HRSA would normally allow.

The U.S. Health Resources and Services Administration said late Friday that when the COVID-19 public health emergency ends on Thursday, so too will a nearly three-year-old policy clarification that lets hospitals under certain conditions dispense 340B drugs at offsite outpatient

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report